Education
About Us
Working with TipRanks
Follow Us
Medicure Inc (TSE:MPH)
:MPH
MPH Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$0.63 - C$1.33
Previous CloseN/A
Volume1.00K
Average Volume (3M)2.27K
Market Cap
C$11.58M
Enterprise ValueC$6.68M
Total Cash (Recent Filing)C$7.22M
Total Debt (Recent Filing)C$876.00K
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Aug 13, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding10,436,313
10 Day Avg. Volume2,106
30 Day Avg. Volume2,270
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$1.00Price Target Upside-9.91% Downside
Rating ConsensusHold
Number of Analyst Covering0
Medicure News
MPH FAQ
What was Medicure Inc’s price range in the past 12 months?
Medicure Inc lowest stock price was C$0.63 and its highest was C$1.33 in the past 12 months.
What is Medicure Inc’s market cap?
Medicure Inc’s market cap is C$11.58M.
When is Medicure Inc’s upcoming earnings report date?
Medicure Inc’s upcoming earnings report date is Aug 13, 2025 which is in 5 days.
How were Medicure Inc’s earnings last quarter?
Currently, no data Available
Is Medicure Inc overvalued?
According to Wall Street analysts Medicure Inc’s price is currently Overvalued.
Does Medicure Inc pay dividends?
Medicure Inc does not currently pay dividends.
What is Medicure Inc’s EPS estimate?
Medicure Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Medicure Inc have?
Medicure Inc has 10,436,313 shares outstanding.
What happened to Medicure Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Medicure Inc?
Currently, no hedge funds are holding shares in TSE:MPH
Company Description
Medicure Inc
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market in Canada and the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers ReDS, a non-invasive medical device that offers measurement of lung fluid for the management of congestive heart failure. Further, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail pharmacies, as well as online. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.
Technical Analysis
Theratechnologies
―
Crescita Therpeutc
―
Mountain Valley MD
―
Medexus Pharmaceuticals Inc
―
Revive Therapeutics
―
Ownership Overview
24.73% Insiders
―
Mutual Funds
― Other Institutional Investors
75.27% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---